Featured Research

from universities, journals, and other organizations

Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma

Date:
July 12, 2011
Source:
JAMA and Archives Journals
Summary:
In a study examining eight eyes that were removed following intra-arterial chemotherapy (IAC) for treatment of retinoblastoma (a tumor of the retina of the eye), there was variable response of the tumor to therapy but also evidence of ocular complications.

In a study examining eight eyes that were removed following intra-arterial chemotherapy (IAC) for treatment of retinoblastoma (a tumor of the retina of the eye), there was variable response of the tumor to therapy but also evidence of ocular complications, according to a report published Online First by Archives of Ophthalmology, one of the JAMA/Archives journals.

Related Articles


According to background information in the article, a new but somewhat controversial treatment for retinoblastoma (Rb) is IAC. In this type of therapy, chemotherapy is delivered directly to the eye and the surrounding area by administering the medication through the ophthalmic artery. "The main goal of this approach is to provide sufficient chemotherapy to eradicate the Rb and avoid the toxicities of systemic chemotherapy," explain the authors.

Ralph C. Eagle, Jr., M.D., from the Wills Eye Institute, Philadelphia, and colleagues examined eight eyes that had been treated with IAC but were later removed (enucleated). The enucleations were performed because the tumors were not responsive to therapy, or because other medical problems, such as a certain type of glaucoma, developed. An ophthalmic pathologist dissected and studied the eyes.

This examination demonstrated that the response to treatment ranged from minimal (one eye), to moderate (one eye), to extensive (four eyes) to complete regression (two eyes). However, a majority of the eyes also showed evidence of complications, including ischemia and atrophy of the retina, blood clots in blood vessels and foreign material within those clots.

"In summary, histopathology of eyes with Rb following IAC showed evidence of complete tumor regression in eyes in which there was clinical tumor regression and also confirmed viable tumor in those in which tumor was suspected clinically," report the authors. However, the authors also emphasize the importance of the discovery of blood vessel blockages and foreign material in the clots within those vessels. The researchers conclude, "We suggest that IAC for Rb be used with caution."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. C. Eagle, C. L. Shields, C. Bianciotto, P. Jabbour, J. A. Shields. Histopathologic Observations After Intra-arterial Chemotherapy for Retinoblastoma. Archives of Ophthalmology, 2011; DOI: 10.1001/archophthalmol.2011.223

Cite This Page:

JAMA and Archives Journals. "Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma." ScienceDaily. ScienceDaily, 12 July 2011. <www.sciencedaily.com/releases/2011/07/110712192232.htm>.
JAMA and Archives Journals. (2011, July 12). Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma. ScienceDaily. Retrieved March 6, 2015 from www.sciencedaily.com/releases/2011/07/110712192232.htm
JAMA and Archives Journals. "Study evaluates eye findings after use of intra-arterial chemotherapy for retinoblastoma." ScienceDaily. www.sciencedaily.com/releases/2011/07/110712192232.htm (accessed March 6, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, March 6, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Bupa Eyes India Healthcare Opportunities

Bupa Eyes India Healthcare Opportunities

Reuters - Business Video Online (Mar. 5, 2015) Bupa is hoping to expand in India&apos;s fast-growing health insurance market, once a rule change on foreign investment is implemented. The British private healthcare group&apos;s CEO tells Grace Pascoe why it&apos;s so keen on the new opportunity. Video provided by Reuters
Powered by NewsLook.com
Doctor in Your Pocket Is Getting Smarter

Doctor in Your Pocket Is Getting Smarter

Reuters - Business Video Online (Mar. 5, 2015) Mobile apps are turning smartphones into a personal doctors, with users able to measure heart rate, blood pressure and even blood sugar. But will it change our behaviour? Ivor Bennett reports from the Mobile World Congress in Barcelona. Video provided by Reuters
Powered by NewsLook.com
AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

AbbVie Inks $21B Deal To Buy Cancer Drugmaker Pharmacyclics

Newsy (Mar. 5, 2015) AbbVie announced Wednesday it will buy cancer drugmaker Pharmacyclics in a $21 billion deal. Video provided by Newsy
Powered by NewsLook.com
Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Toddlers Drinking Coffee? Why You Shouldn't Share Your Joe

Newsy (Mar. 5, 2015) A survey of Boston mothers and toddlers found that 15 percent of two-year-olds drink coffee and 2.5 percent of 1-year-olds. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins